Login to Your Account

Clinic Roundup

Thursday, March 3, 2011
The European Medicines Agency gave Vical Inc., of San Diego, scientific advice pertaining to its endpoints for a Phase III trial of TransVax, a cytomegalovirus vaccine. The EMA said that a CMV disease endpoint was not practical, because of the low incidence of CMV disease and the small size of the target population. Vical is also working on plans for a pivotal Phase III trial with the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription